Cadila Healthcare gets OAI letter from USFDA for Moraiya facility
The company has received a letter from the USFDA classifying the inspection conducted at its Moraiya facility from April 22 to May 3 as OAI, Cadila Healthcare said in a filing to the BSE.
New Delhi: Drug firm Cadila Healthcare on August 7 said the US health regulator has classified inspection of the company's Moraiya facility in Gujarat as 'official action indicated' (OAI).
According to the United States Food and Drug Administration (USFDA), OAI means regulatory and/or administrative actions will be recommended.
Read Also: Zydus Cadila completes phase III trial of Diabetes drug Lipaglyn in India
The company has received a letter from the USFDA classifying the inspection conducted at its Moraiya facility from April 22 to May 3 as OAI, Cadila Healthcare said in a filing to the BSE.
"The company believes that this classification will not have any impact on the current supplies or revenues of this facility," it added.
Cadila Healthcare is in the process of sending further updates of its corrective actions to the USFDA and remains hopeful of a positive outcome, the company said.
Read Also: Zydus Cadila wins USFDA nod for Minocycline Hydrochloride ER tablets to treat acne
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd